Enclomiphene vs Methylene Blue
Well Studied vs Well Studied
avoid Mechanism-based · 64% Both Enclomiphene and Methylene Blue carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Enclomiphene Methylene Blue
Weight 405.96 Da 319.85 Da
Half-life ~10 hours ~5-6 hours
Type Trans-isomer of clomifene (selective estrogen receptor modulator) Phenothiazine dye (C16H18ClN3S)
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Methylene Blue
01 Enhances mitochondrial respiration and ATP production by acting as an alternative electron carrier
02 Reduces mitochondrial reactive oxygen species generation
03 Supports memory consolidation and cognitive performance at low doses
04 Neuroprotective effects demonstrated in models of Alzheimer's, Parkinson's, and traumatic brain injury
05 Improves mitochondrial function in aging cells and tissues
06 FDA-approved treatment for acquired methemoglobinemia
07 Anti-inflammatory and antimicrobial properties
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Methylene Blue
Blue or blue-green discoloration of urine (expected and harmless)
Blue-green staining of the tongue and mouth with liquid formulations
Mild nausea or stomach discomfort, especially at higher doses
Blue discoloration of stool
Mild headache during initial use
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Concurrent use of SSRIs, SNRIs, or MAO inhibitors (serotonin syndrome risk)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk of severe hemolytic anemia)
Renal insufficiency (methylene blue is primarily renally excreted)
Known hypersensitivity to methylene blue or phenothiazine compounds
Pregnancy and breastfeeding (insufficient safety data)
Research Evidence
Enclomiphene Methylene Blue
Status Well Studied Well Studied
References 5 studies 5 studies
Latest — 2017
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.